Form 4 for XENE Xenon Pharmaceuticals Inc.
Accepted 2026-01-02 00:00:00 ET · period of report 2026-01-02 · accession 0001193125-26-001172 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-01-02 | 2026-01-02 | XENE | MORTIMER IAN | Pres, CEO, Dir | S - Sale+OE | $44.43 | -40.0K | 6,000 | -87% | -$1.78M |
| DT | 2026-01-02 | 2026-01-02 | XENE | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $7.49 | +40.0K | 46.0K | +667% | +$299.6K |
| DT | 2026-01-02 | 2026-01-02 | XENE | MORTIMER IAN | Pres, CEO, Dir | M - OptEx | $0.00 | -40.0K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-01-02 | S | D | 37,938 | $44.40 | 8,062 | D | — | — | (F2) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $43.91 to $44.90, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 2 | Common | Common Shares | 2026-01-02 | M | A | 40,000 | $7.49 | 46,000 | D | — | — | |
| 3 | Common | Common Shares | 2026-01-02 | S | D | 2,062 | $44.93 | 6,000 | D | — | — | (F3) The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price (rounded to two decimal places), respectively, of shares sold. These share were sold in multiple transactions at prices ranging from $44.91 to $45.125, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| 4 | Derivative | Stock Option (Right to Buy) | 2026-01-02 | M | D | 40,000 | $0.00 | 0 | D | $7.49 · — to 2026-03-10 | 40,000 Common Shares | (F4) The shares subject to the option are fully vested and exercisable. |